The U.S. Drug Enforcement Agency announced in late April 2024 that it plans to ease federal restrictions on cannabis[1], reclassifying it from a Schedule I drug to the less restricted Schedule III, which includes drugs such as Tylenol with codeine, testosterone and other anabolic steroids[2]. This historic shift signals an acknowledgment of the promising medicinal value of cannabis[3].
The move comes in tandem with growing...